The Patentability of Human Embryonic Stem Cells in Europe

Gerard Porter; Chris Denning; Aurora Plomer; John Sinden; Paul Torremans

doi:10.1038/nbt0606-653

The Patentability of Human Embryonic Stem Cells in Europe

Gerard Porter, Chris Denning, Aurora Plomer, John Sinden, Paul Torremans

School of Law

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The article examines the impact of the directive by the European Patent Office on human embryonic stem (hES) cells patenting strategy and its implications on biotechnology industries in Europe. The rule 23 section c of the European Patent Convention directive had prohibited patent protection for hES cell-related technology. This restriction caused patentees to engage in differential wording strategy such as the used restrictive language which limit the commercial value and scope of the technology.

Original language	English
Pages (from-to)	653-65
Journal	Nature Biotechnology
Volume	24
Issue number	6
DOIs	https://doi.org/10.1038/nbt0606-653
Publication status	Published - 2006

Access to Document

10.1038/nbt0606-653

Cite this

@article{f3b494fb3c4f4ada9941855561149113,

title = "The Patentability of Human Embryonic Stem Cells in Europe",

abstract = "The article examines the impact of the directive by the European Patent Office on human embryonic stem (hES) cells patenting strategy and its implications on biotechnology industries in Europe. The rule 23 section c of the European Patent Convention directive had prohibited patent protection for hES cell-related technology. This restriction caused patentees to engage in differential wording strategy such as the used restrictive language which limit the commercial value and scope of the technology.",

author = "Gerard Porter and Chris Denning and Aurora Plomer and John Sinden and Paul Torremans",

year = "2006",

doi = "10.1038/nbt0606-653",

language = "English",

volume = "24",

pages = "653--65",

journal = "Nature Biotechnology",

issn = "1087-0156",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - The Patentability of Human Embryonic Stem Cells in Europe

AU - Porter, Gerard

AU - Denning, Chris

AU - Plomer, Aurora

AU - Sinden, John

AU - Torremans, Paul

PY - 2006

Y1 - 2006

N2 - The article examines the impact of the directive by the European Patent Office on human embryonic stem (hES) cells patenting strategy and its implications on biotechnology industries in Europe. The rule 23 section c of the European Patent Convention directive had prohibited patent protection for hES cell-related technology. This restriction caused patentees to engage in differential wording strategy such as the used restrictive language which limit the commercial value and scope of the technology.

AB - The article examines the impact of the directive by the European Patent Office on human embryonic stem (hES) cells patenting strategy and its implications on biotechnology industries in Europe. The rule 23 section c of the European Patent Convention directive had prohibited patent protection for hES cell-related technology. This restriction caused patentees to engage in differential wording strategy such as the used restrictive language which limit the commercial value and scope of the technology.

U2 - 10.1038/nbt0606-653

DO - 10.1038/nbt0606-653

M3 - Article

SN - 1087-0156

VL - 24

SP - 653

EP - 665

JO - Nature Biotechnology

JF - Nature Biotechnology

IS - 6

ER -

The Patentability of Human Embryonic Stem Cells in Europe

Abstract / Description of output

Access to Document

Fingerprint

Cite this